Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.

about

Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis: Methodological issues.

P2860

Q50079692-537B7194-97AF-404D-886E-E853462038E3

P2860

Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q50918813

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@en

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@nl

type

Item

label

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@en

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@nl

prefLabel

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@en

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@nl

P1476

Serum interleukin-6 and surviv ...... ablished rheumatoid arthritis.

@en

P2093

Bahaerguli Litifu

http://www.w3.org/2001/XMLSchema#string

Muzhi Chen

http://www.w3.org/2001/XMLSchema#string

Rui Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Survivin study: what is the next wave?

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells.

P304

126-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14397595.2017.1317384

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28657833

http://www.w3.org/2001/XMLSchema#string

Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.

about

P2860

P2860

Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698